Remuneration Information • May 5, 2015
Preview not available for this file type.
Download Source FileCopenhagen, 2015-05-05 11:42 CEST (GLOBE NEWSWIRE) -- 5 May 2015 - Zealand
Pharma A/S (Nasdaq Copenhagen: ZEAL) (”Zealand”) announces the grant of
warrants to the company’s Executive Management and employees. The warrants are
granted under warrant programs covered by the authority pursuant to Section 8.1
and 8.4 of Zealand’s Articles of Association, adopted at the General Meeting on
2 November 2010 and the General Meeting on 21 April 2015.
The warrant programs are incentive schemes reflecting Zealand’s objective to
attract and retain first-rate employees and help ensure common short and long
term interests between the management and the shareholders of the company.
A total of 512,609 warrants have been granted, giving the rights to
subscription of up to 512,609 new Zealand shares with a nominal value of DKK 1
each and corresponding to 2.2% of the company’s total outstanding share
capital. The exercise price is fixed at DKK 101.20 reflecting the closing price
of Zealand’s shares on Nasdaq Copenhagen on Monday 4 May 2015 plus 10%.
The exercise of the warrants may take place, in whole or in part, in defined
time windows from 5 May 2018 until and including 5 May 2020. The warrants
granted to President and CEO, Britt Meelby Jensen, may be exercised, in whole
or in part, in defined time windows from 5 May 2016 until and including 5 May
2020. The exercise windows for all granted warrants are defined as four weeks
following the publication of Zealand’s full year reports or interim reports for
the first quarter, first half or first nine months, respectively.
The total number of new warrants granted to Executive Management and employees
has a market value of DKK 16,212,525 calculated on basis of the Black-Scholes
model including a 180 days historic volatility of 43.7%, a 5-year risk free
interest rate of -0.1% and a share price of DKK 92.00.
Pursuant to Section 28a of the Danish Securities Trading Act, Zealand shall
report transactions in the company’s shares and related securities by
managerial employees and their related parties. In this regard, Zealand reports
the following transactions in connection with the grant of warrants:
?????
For further information, please contact:
Britt Meelby Jensen, President and Chief Executive Officer
Tel: +45 51 67 61 28, email: [email protected]
Hanne Leth Hillman, Senior Vice President for Communications and Investor
Relations
Tel: +45 50 60 36 89, email: [email protected]
About Zealand Pharma
Zealand Pharma A/S (“Zealand”) (Nasdaq Copenhagen: ZEAL) is a biotechnology
company based in Copenhagen, Denmark. Zealand has leading expertise in the
discovery, design and development of novel peptide medicines and possesses
in-house competences also in clinical trial design and management with a
therapeutic focus on metabolic diseases and acute care indications. The company
is advancing a pipeline of novel wholly-owned medicines in development
alongside a partnered product and development portfolio.
Zealand’s first invented medicine, lixisenatide, a once-daily prandial GLP-1
agonist for the treatment of Type 2 diabetes, is marketed globally (ex-US) as
Lyxumia® and in Phase III development as a single-injection combination with
Lantus® (LixiLan), both under a global license agreement with Sanofi. US
regulatory submission of Lyxumia® is planned for Q3 2015 with US and EU
regulatory submissions of LixiLan expected in Q4 2015 and Q1 2016,
respectively.
Zealand’s wholly-owned products include danegaptide (prevention of Ischemic
Reperfusion Injury) in Phase II and the stable glucagon product, ZP4207
(treatment of severe hypoglycemia) in Phase I as well as several preclinical
peptide therapeutics. Partnering represents an important component of strategy
to leverage in-house expertise, share development risk in large clinical
trials, provide funding and commercialize the company’s products. Zealand
currently has global license agreements and partnerships with Sanofi, Helsinn
Healthcare, Boehringer Ingelheim and Eli Lilly.
For further information: www.zealandpharma.com Follow us on
Twitter @ZealandPharma
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.